Studies determine that both RA and PsA are autoimmune diseases and link disease susceptibility to certain alleles that encode the major histocompatibility complex, HLA
Mary Beth Nierengarten is a writer, editor and journalist with over 25 years of medical communications experience. She is a regular contributor to a number of online and print publications and writes in most clinical areas, as well as on health policy and economic issues. She lives in Minneapolis and can be reached at [email protected].
Articles by Mary Beth Nierengarten
2013 ACR/ARHP Annual Meeting: Researchers Explore Role of Pathogens, Quality of Care in Rheumatoid Arthritis
Funding by the Rheumatology Research Foundation has furthered studies on the impact of infectious agents and autoantigens, periodontal disease, and disease-modifying antirheumatic drugs on patients with RA
2013 ACR/ARHP Annual Meeting: The Rheumatoid Arthritis Treatment Debate
Discussion by rheumatologists on the merits of biologics vs. triple therapy for patients with RA lends insight into therapeutic alternatives
2013 ACR/ARHP Annual Meeting: Rheumatology Year in Review
Progress in treatments for pediatric rheumatic diseases, collaborative clinical trials, and personalized therapeutic approaches highlight the past year in rheumatology
PR-COIN Initiative Takes Aim at Juvenile Idiopathic Arthritis
The Pediatric Rheumatology Care and Outcomes Improvement Network uses clinical evidence and a network of collaborators to improve outcomes for children with JIA
Negotiating Tips for Careers in Private Practice, Academia, and Industry
Rheumatologists need to be aware of the fine art of negotiating contracts when seeking employment. Here are some tips.
ACR/ARHP Annual Meeting 2012: Fatigue for People with Rheumatoid Arthritis Rooted in Physiological and Psychological Factors
Researchers find that genes, gender, and cognition all contribute to fatigue in rheumatoid arthritis (RA)
ACR/ARHP Annual Meeting 2012: What Rheumatologists Need to Know about the New Oral Anticoagulants
A hematologist outlines how the new drugs can help treat coagulation triggered by rheumatological diseases
ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
Rituximab established as the drug of choice in patients with severe disease relapse, though cyclophosphamide may still play an important role for some patients, say rheumatologists
ACR/ARHP Annual Meeting 2012: Early Signs of Rheumatoid Arthritis May Appear Outside the Joints
Evidence that suggests rheumatoid arthritis (RA) starts in mucosal sites such as the oral cavity and lung may lead to improved treatment and prevention of the disease